Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists.
Stewart
J A
JA
Vermont Regional Cancer Center, University of Vermont, Burlington 05401.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects*; D016597:Trimetrexate
D000970:Antineoplastic Agents; D011799:Quinazolines; D016597:Trimetrexate